RNA and Biomolecule-delivery

DIVERSA is a European deep‑tech biotechnology company developing advanced nanodelivery technologies for RNA‑based therapeutics, with a strong focus on complex indications where delivery is the main barrier to clinical and commercial success, particularly in solid tumors and localized gene and immunomodulatory therapies.

At the core of DIVERSA’s therapeutic strategy is its proprietary Sphingolipid Nanoparticle (SNP) platform, engineered to enable controlled, localized intracellular delivery of RNA payloads.

Beyond its own therapeutic developments, DIVERSA positions itself as a technology‑enabling partner for pharma and biotech companies, supporting RNA programs across multiple stages of development. The company works alongside partners to optimize delivery systems, improve translational performance and advance programs across critical development milestones, bridging gaps between early proof‑of‑concept, advanced preclinical development and clinical readiness. Unlike conventional lipid nanoparticles (LNPs), SNPs are designed to perform in challenging tissue environments, addressing key limitations such as insufficient localization, off‑target exposure and limited translational robustness in solid tissues. This patented platform establishes a strong and defensible Freedom to Operate (FTO), enabling partners to develop RNA therapeutics without exposure to the dense IP landscape surrounding LNP technologies, which is largely controlled by non‑European players.

In parallel, DIVERSA has developed Sphingolipid Nanoemulsions (SNs) as a complementary platform addressing a broader range of biomolecules and non‑gene‑therapy applications. SNs are optimized for the formulation, stabilization and delivery of recombinant proteins, peptides, enzymes and other bioactive compounds, where solubility, bioavailability and local penetration are key challenges.

This SN platform enables applications across dermatology and skin delivery, dermo‑cosmetics, nutraceuticals, consumer health and applied life‑science markets, offering partners advanced delivery solutions without the regulatory complexity of gene therapies. SNs support local and topical delivery approaches and allow DIVERSA to collaborate with companies seeking formulation differentiation, performance enhancement or accelerated development of biomolecule‑based products.

Together, SNPs and SNs position DIVERSA as a multi‑platform delivery partner, capable of addressing both high‑complexity RNA therapeutics and broader biomolecule delivery needs, offering partners flexibility, reduced development risk and access to a coherent sphingolipid‑based technology ecosystem.